Dalbavancin: A review

Drugs of Today

Volumn 43, Issue 5, 2007, Pages 305-316

  Scheinfeld, Noah ^a  

^a METROPOLITAN HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 40926; CEFALEXIN; CEFAZOLIN; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DX 619; GLYCOSYLTRANSFERASE; ICLAPRIM; LINEZOLID; MDL 63246; ORITAVANCIN; PEPTIDOGLYCAN; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; RANBEZOLID; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; WCK 771;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL CELL WALL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENDOCARDITIS; ENTEROCOCCAL INFECTION; FEVER; GRAM POSITIVE BACTERIUM; HEADACHE; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INDWELLING CATHETER; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; RED MAN SYNDROME; REVIEW; SEPTICEMIA; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; THRUSH; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TEICOPLANIN;

EID: 34447131546     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.5.1088618     Document Type: Review

References (64)

1. Fridkin, S.K., Hageman, J.C., Morrison, M. et al. Methicillin- resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352: 1436-44.
2. Appelbaum, P.C., Jacobs, M.R. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol 2005, 8: 510-7.
3. Pope, S.D., Roecker, A.M. Dalbavancin: A novel lipoglycopeptide antibacterial. Pharmacotherapy 2006, 26: 908-18.
4. Baquero, F. Gram-positive resistance: Challenge for the development of new antibiotics. J Antimicrob Chemother 1997, 39 (Suppl. A): 1-6.
5. Excerpt from annual communicable disease report 2002. Washington State Department of Health. Appendix 4. 106-9. Available at: http://www.doh.wa.gov/ Topics/Antibiotics/applV.pdf. Accessed January 31, 2006.
6. Frazee, B.W., Lynn, J., Charlebois, E.D., Lambert, L., Lowery, D., Perdreau-Remington, F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005, 45: 311-20.
7. Kuehnert, M.J., Hill, H.A., Kupronis, B.A., Tokars, J.I., Solomon, S.L., Jernigan, D.B. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis (serial on the Internet). June 2005 (date cited). Available at: http://www.cdc.gov/ncidod/EID/vol11no06/04-0831.htm.
8. Kopp, B.J., Nix, D.E., Armstrong, E.P. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004, 38: 1377-82.
9. Hamilton-Miller, J.M. Vancomycin-resistant Staphylococcus aureus: A real and present danger? Infection 2002, 30: 118-24.
10. Small, P.M., Chambers, H.F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990, 34: 1227-31.
11. Cantoni, L., Glauser, M.P., Bide, J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 1990, 34: 2348-53.
12. Dang, C.N., Prasad, Y.D., Boulton, A.J., Jude, E.B. Methicillin- resistant Staphylococcus aureus in the diabetic foot clinic: A worsening problem. Diabet Med 2003, 20: 159-61.
13. Steiert, M., Schmitz, F.J. Dalbavancin (Biosearch Italia/Versicor). Curr Opin Investig Drugs 2002, 3: 229-33.
14. Beauregard, D.A., Williams, D.H., Gwynn, M.N., Knowles, D.J. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother 1995, 39: 781-5.
15. Van Bambeke, F., Van Laethem, Y., Courvalin, P., Tulkens, P.M. Glycopeptide antibiotics: From conventional molecules to new derivatives. Drugs 2004, 64: 913-36
16. Hoffman-Roberts, H.L., Babcock, E., Mitropoulos, I.F. Investigational new drugs for the treatment of resistant pneumococcal infections. Expert Opin Investig Drugs 2005, 14: 973-95.
17. Leimkuhler, C., Chen, L., Barrett, D. et al. Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics. J Am Chem Soc 2005, 127: 3250-1.
18. Bozdogan, B., Ednie, L., Credito, K., Kosowska, K., Appelbaum, P.C. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother 2004, 48: 4762-5.
19. Bradley, J.S. Newer antistaphylococcal agents. Curr Opin Pediatr 2005, 17: 71-7.
20. Anstead, G.M., Owens, A.D. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis 2004, 17: 549-55.
21. Torres-Viera, C., Dembry, L.M. Approaches to vancomycin-resistant enterococci. Curr Opin Infect Dis 2004, 17: 541-7.
22. Bozdogan, B., Esel, D., Whitener, C., Browne, F.A., Appelbaum, P.C. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003, 52: 864-8
23. Van Bambeke, F. Glycopeptides in clinical development: Pharmacological profile and clinical perspectives. Curr Opin Pharmacol 2004, 4: 471-8.
24. Raghavan, M., Linden, P.K. Newer treatment options for skin and soft tissue infections. Drugs 2004, 64: 1621-42.
25. Anderegg, T.R., Biedenbach, D.J., Jones, R.N.; Quality Control Working Group. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity. J Clin Microbiol 2003, 41: 2795-6.
26. Jauregui, L.E., Babazadeh, S., Seltzer, E. et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41: 1407-15.
27. Vicuron Pharmaceuticals press release, August 12, 2004. Vicuron Pharmaceuticals, Inc. (MICU) announces positive pivotal phase III results for dalbavancin in skin and soft tissue infections. Available at: http://www. biospace.com/news_story.aspx?StoryID= 17075320&full=1.
28. Dowell, J.A., Seltzer, E., Buckwalter, M., Marbury, T. The pharmacokinetics of dalbavancin (DAL) in subjects with mild, moderate or severe hepatic impairment (HI). 44th International Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 2004: 4, Abst.
29. Candiani, G., Abbondi, M., Borgonovi, M., Romano, G., Parenti, F. In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999, 44: 179-92.
30. Lefort, A., Pavie, J., Garry, L., Chau, F., Fantin, B. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother 2004, 48: 1061-4.
31. Jabes, D., Candiani, G., Romano, G., Brunati, C., Riva, S., Cavaleri, M. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004, 48: 1118-23.
32. Cavaleri, M., Riva, S., Valagussa, A. et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005, 55 (Suppl. 2): H31-5.
33. Leighton, A., Gottlieb, A.B., Dorr, M.B. et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004, 48: 940-5.
34. Streit, J.M., Fritsche, T.R., Sader, H.S., Jones, R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48: 137-43.
35. Mushtaq, S., Warner, M., Johnson, A.P., Livermore, D.M. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. J Antimicrob Chemother 2004, 54: 617-20.
36. Gales, A.C., Sader, H.S., Jones, R.N. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005, 11: 95-100.
37. Lopez, S., Hackbarth, C., Romano, G., Trias, J., Jabes, D., Goldstein, B.P. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005, 55 (Suppl. 2): 21-4.
38. Jones, R.N., Biedenbach, D.J., Johnson, D.M., Pfaller, M.A. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother 2001, 13: 244-54.
39. Goldstein, E.J., Citron, D.M., Merriam, C.V., Warren, Y., Tyrrell, K., Fernandez, H.T. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 2003, 47: 1968-71.
40. Flamm, R.K., Draghi, D.C., Karlowsky, J.A., Sahm, D.F. Activity of dalbavancin against clinical isolates of Staphylococci and Streptococci from the U.S. and Europe. 44th International Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 2004: 173, Abst.
41. Scheinfeld, N. Dalbavancin: A review for dermatologists. Dermatol Online J 2006, 12(4): 6.
42. Leighton, A., Mroszcak, E., White, R. et al. Dalbavancin: Phase 1 single and multiple-dose placebo controlled intravenous safety pharmacokinetic study in healthy volunteers. 41st Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago 2001, Abst. 951.
43. Cavaleri, M., Cooper, A., Nutley, M.A., Stognew, M. Protein binding of dalbavancin using isothermal titrationo microcalorimetry. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002, Abst. A-1385.
44. Guay, D.R. Dalbavancin: An investigational glycopeptide. Expert Rev Anti Infect Ther 2004, 2: 845-52.
45. Dorr, M.B., Jabes, D., Cavaleri, M. et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005, 55 (Suppl. 2): ii25-30.
46. Seltzer, E., Dorr, M.B., Goldstein, B.P., Perry, M., Dowell, J.A., Henkel, T.; Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37: 1298-303.
47. Goldstein, B.P., Draghi, D.C., Sheehan, D.J., Hogan, P., Sahm, D.F. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007, 51: 1150-4.
48. Cavaleri, M., Riva, S., Valagussa, A. et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005, 55 (Suppl. 2): 31-5.
49. Seltzer, E., Goldberg, L., Krause, D. Safety of dalbavancin in a clinical development program. 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, D.C., 2005, Abst. L-1576.
50. Darouiche, R.O., Mansouri, M.D. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J Infect 2005, 50: 206-9.
51. Malabarba, A., Goldstein, B.P. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005, 55 (Suppl. 2): ii15-20.
52. Lopez, S., Hackbarth, C., Romano, G., Trias, J., Jabes, D., Goldstein, B.P. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005, 55 (Suppl. 2): H21-4.
53. Streit, J.M., Sader, H.S., Fritsche, T.R., Jones, R.N. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005, 53: 307-10.
54. Lin, G., Credito, K., Ednie, L.M., Appelbaum, P.C. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005, 49: 770-2.
55. Jones, R.N., Sader, H.S., Fritsche, T.R., Stilwell, M. The Jones Group/JMI Laboratories. Comparative activity of dalbavancin tested against 7,771 isolates from the USA and Europe (2003). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 2004, Poster E-2009.
56. Edmiston, C.E. Jr., Goheen, M.P., Seabrook, G.R. et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006, 192: 344-54.
57. Mathur, T., Singhal, S., Khan, S., Upadhyay, D., Fatma, T., Rattan, A. Adverse effect of staphylococci slime on in vitro activity of glycopeptides. Jpn J Infect Dis 2005, 58: 353-7.
58. Raad, I., Darouiche, R., Vazquez, J. et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related blood-stream infection caused by gram-positive pathogens. Clin Infect Dis 2005, 40: 374-80.
59. Jauregui-Paredo, L., O'Riordan, W., Goldberg, L., Wible, M., Seltzer, E. Efficacy and safety of weekly dalbavancin versus linezolid in complicated skin and skin structure infections. 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, D.C., 2005, Abst. L-1575.
60. Goldstein, B., Seltzer, E., Flamm, R., Sahm, D. Dalbavancin phase 3 skin and skin structure (SSSI) studies: Pathogens and microbiological efficacy. 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, D.C., 2005, Abst. L-1577.
61. Campbell, K.C., Kelly, E., Targovnik, N. et al. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol 2003, 14: 157-68; quiz 170-1.
62. DrugDevelopment Technology. Dalbavancin - Second-generation glycopeptide for serious Gram-positive infections. Available at: http://www.drugdevelopment-technology.com/projects/dalvabancin/.
63. Shah, P.M. The need for new therapeutic agents: What is the pipeline? Clin Microbiol Infect 2005, 11 (Suppl. 3): 36-42.
64. Padmanabhan, R.A., Larosa, S.P., Tomecki, K.J. What's new in antibiotics? Dermatol Clin 2005, 23: 301-12.